MEDICAL DEVICES VENTURE – Route 2023 – 01/03/2023 – 08:30

Paris, January 3, 2022

The society MEDICAL DEVICES ENTERPRISELaunched in 2021, listed on the stock exchange since February 2022, its mission is to invest in Deeptech and MedTech research projects resulting from French research and to accelerate the deployment of Start Ups in France and internationally.

MEDICAL DEVICES VENTURE already has 4 majority stakes in strong development:


More than 15 million people each year suffer a cardiovascular accident and most post-stroke patients lose hand dexterity, which causes a significant impairment in daily life gestures.

Dextrain is the result of 10 years of research that combines technology (with high-precision force sensors), neurorehabilitation and artificial intelligence to offer patients digital therapy suites to train their hand dexterity recovery.

Dextrain in one year won the SOFMER award, the REEDUCA award, was Deeptech approved, won an ANR project, named ILAB and, above all, convinced large rehabilitation centers to adopt DEXTRAIN Manipulandum.

The perspectives for DEXTRAIN from 2023 are to allow patients to train from home, being in permanent contact with their healthcare professional.


More than a third of the world’s population suffers from more or less serious skin problems (acne, herpes zoster, psoriasis, eczema, herpes, lupus, dermatitis, melanoma, carcinoma) and the environmental impact exacerbates these problems.

For 10 years, faced with the lack of a database of photos of standardized lesions and the lack of specialists in prevention and dermatologists, a research team wanted to create an innovative solution, usable from home.

Poladerme was designed to combine the functions of a dermoscope connected to spectropolarimetry and artificial intelligence, to complete the lesion assessment.

The first samples will be distributed in the first quarter of 2023 to dermatology centers and marketing will be effective in 2023.

The aim is to be able to offer Poladerme to as many people as possible by the end of 2023 for rent at €15 per month or for a purchase of €300 including tax.


Faced with a medical desert and a problem of access to care, it was urgent to present a solution capable of improving the quality of life of patients to:

  • Chronic diseases
  • the postoperative
  • age well

DOMISANTE is an innovative and unique solution that offers teleconsultation services from home, a kit of connected health objects for constant monitoring, remote care, scheduling appointments for scheduled appointments, health space and TV.surveillance.

It is a secure and personal platform presented in the form of a medical bag

Offered to health professionals by their patient for 30 euros per month from April 2023, DOMISANTE is the permanent link between caregivers and their patients for prevention, diagnosis and follow-up. In France alone, it is estimated that more than 3 million people are fragile and need weekly monitoring, a number to be multiplied by 5 on a European scale.


Faced with the realization that hospitals had specific technological needs and no response from manufacturers in terms of ergonomics, installation or personalization, MEDICAL DEVICES VENTURE launched MDV IT to offer integrated tailor-made offers, from smartphones to tablets, computers, Panel PCs or interactive whiteboards

MDV IT is also focused on the patient’s home to enable caregivers, nurses and caregivers to have technology for better patient monitoring at home.

Panorama :

MEDICAL DEVICES VENTURE intends to invest in 3 new innovative projects in 2023 to achieve 7 majority stakes in DEEPTECH and MEDTECH.

In addition, MEDICAL DEVICES VENTURE is studying the acquisition files of medical device distributors to provide their start-ups with an expert sales force.

MEDICAL DEVICES VENTURES, an impact company, wants to position itself as the operational and industrial bridge of French academic research in the coming years.


About the Medical Devices Venture:

A subsidiary of ARCHOS, Medical Devices Venture is a holding company that develops a portfolio of investments in medical technology startups. The objective is to combine the expertise of researchers in hospitals and universities with the industrialization, certification and marketing strength of the group. More information:
Loic Poirier, CEO,

Leave a Comment